Nitric oxide bioavailability is also regulated by the cGMP pathway in L-NAME hypertensive cardiomyopathy of rats.

被引：0
|
作者：
Ferreira-Melo, S [1 ]
Yugar-Toledo, JC [1 ]
Souza, WA [1 ]
Thomaz, AJ [1 ]
Franchini, KG [1 ]
Coelho, OR [1 ]
de Lucca, I [1 ]
Moreno, H [1 ]
机构：
[1] UNICAMP, Campinas, SP, Brazil
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 75卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2003.11.047
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P13 / P13
页数：1
相关论文
共 50 条
  • [21] The effect of a nitric oxide inhibitor (L-NAME) on peritoneal transport during dialysis in rats
    Breborowicz, A
    Wieczorowska-Tobis, K
    Korybalska, K
    Polubinska, A
    Radkowski, M
    Oreopoulos, DG
    PERITONEAL DIALYSIS INTERNATIONAL, 1998, 18 (02): : 188 - 192
  • [22] EFFECT OF CHRONIC LOW-DOSE L-NAME TREATMENT ON NITRIC OXIDE SYNTHESIS AND ENDOTHELIAL FUNCTION IN SPONTANEOUSLY HYPERTENSIVE RATS
    Balis, P.
    Puzserova, A.
    Slezak, P.
    Kopincova, J.
    Bernatova, I.
    JOURNAL OF HYPERTENSION, 2010, 28 : E498 - E499
  • [23] Augmentation of high molecular weight kininogen and reduction of kallikrein activity in plasma of L-NAME hypertensive rats.
    Sendäo, AP
    Poggi, JC
    Bendhack, LM
    Reis, ML
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R337 - R337
  • [24] ANTIHYPERTENSIVE AND ANTIHYPERLIPIDEMIC ACTIVITIES OF THYMOQUINONE IN L-NAME HYPERTENSIVE RATS
    Azzubaidi, Marwan S.
    Noor, Noriah M.
    Mizher, Hussam A.
    JOURNAL OF HYPERTENSION, 2015, 33 : E7 - E8
  • [25] Preglomerular sudanophilia in L-NAME hypertensive rats - Involvement of endothelin
    Bouriquet, N
    Dupont, M
    Herizi, A
    Mimran, A
    Casellas, D
    HYPERTENSION, 1996, 27 (03) : 382 - 391
  • [26] L-NAME in the cardiovascular system - nitric oxide synthase activator?
    Kopincova, Jana
    Puzserova, Angelika
    Bernatova, Ivete
    PHARMACOLOGICAL REPORTS, 2012, 64 (03) : 511 - 520
  • [27] L-NAME in the cardiovascular system — nitric oxide synthase activator?
    Jana Kopincová
    Angelika Púzserová
    Iveta Bernátová
    Pharmacological Reports, 2012, 64 : 511 - 520
  • [28] Spironolactone prevents L-NAME-induced hypertension by improving nitric oxide/cGMP pathway
    Pechanova, O.
    Matuskova, J.
    Jendekova, L.
    Kojsova, S.
    Paulis, L.
    Simko, F.
    JOURNAL OF HYPERTENSION, 2006, 24 : S100 - S100
  • [29] Spironolactone improves nitric oxide/cGMP pathway in L-name-induced hypertension.
    Pechanova, Olga
    Matuskova, Jana
    Paulis, Luclovit
    Simko, Fedor
    JOURNAL OF HYPERTENSION, 2006, 24 : 346 - 346
  • [30] The effect of the nitric oxide synthesis inhibitor L-NAME on amitriptyline-induced hypotension in rats
    Tuncok, Y
    Kalkan, S
    Murat, N
    Arkan, F
    Guven, H
    Aygoren, O
    Kurt, S
    JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 2002, 40 (02): : 121 - 127
12345